Otros idiomas Takeda Pharmaceutical Company Limited Sapporo S.E.

Acciones

4502

JP3463000004

Mercado cerrado - Sapporo S.E. Otros sitios de cotización 01:53:52 11/03/2024			Varia. Cinco días.	Varia. 1 de enero.
4.300 ^JPY	-1,15 %		-.--%	+8,18 %

16/05	Takeda Canadá completa la fase de carta de intenciones para el tratamiento del citomegalovirus postrasplante	MT
15/05	La vacuna contra el dengue de Takeda Pharmaceutical recibe la precalificación de la OMS	MT

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Inscripción 100% Gratuita

Evotec steigt aus Gentherapie-Geschäft aus - Ergebniseinbruch zum Jahresstart	22/05
TAKEDA PHARMACEUTICAL : Form 6-K	21/05
Takeda Canada Completes LOI Stage for Post-Transplant Cytomegalovirus Treatment	16/05
Takeda Canada Inc. concludes Letter of Intent (LOI) with the pan-Canadian Pharmaceutical Alliance (pCPA) for LIVTENCITY® (maribavir) for the treatment of adults with a post-transplant cytomegalovirus (CMV) infection	16/05
Takeda Pharmaceutical's Dengue Vaccine Granted WHO Prequalification	15/05
FDA extends review of Ascendis Pharma's hormone disorder therapy	14/05
Scilex Holding Says Federal Court Approved Settlement With Takeda Pharmaceutical in Gloperba Patent Dispute	14/05
Scilex Holding Says Federal Court Approved Settlement With Takeda Pharmaceutical in Gloperba Patent Dispute	14/05
Takeda to Present Oncology Portfolio and Pipeline Data at the 2024 ASCO Annual Meeting	14/05
Sector Update: Health Care Stocks Mixed Late Afternoon	13/05
Sector Update: Health Care	13/05
Top Midday Gainers	13/05
AC Immune Enters Licensing Deal for Alzheimer's Disease Drug Candidate	13/05
Takeda Pharmaceutical, AC Immune Agree to Option and Licence Agreement, Including on Alzheimer's Treatment Candidate	13/05
AC Immunity Shares Soar on Exclusive License Deal with Takeda	13/05
AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer’s Disease	13/05
Takeda Announces Enterprise-wide Program to Support Growth and Deliver Core Operating Profit Margin Improvement	10/05
Takeda Pharmaceutical, Announces full-year 2023 results and outlook for 2024 Emphasizes commitment to late-stage pipeline development and core operating margin improvement	10/05
Takeda annonce ses résultats pour l’exercice 2023 et ses perspectives pour l’exercice 2024, confirmant son engagement en faveur du développement d’un portefeuille de produits à un stade avancé et de l’augmentation de la marge bénéficiaire...	10/05
Takeda Pharmaceutical's Attributable Profit Falls 55% in Fiscal 2024	10/05

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas Takeda Pharmaceutical Company Limited Sapporo S.E.

Acciones

4502

JP3463000004

Otros idiomas

Filtros